Ivan Kairatov is a seasoned biopharma expert with a distinguished background in research and development, focusing specifically on the intersection of immunology and biotechnology. With years of experience analyzing the clinical and commercial trajectories of next-generation therapies, he has
The prevailing wisdom that all physical activity is created equal has faced a significant challenge as researchers uncover the profound physiological and psychological differences between voluntary exercise and mandatory toil. While medical professionals frequently advocate for increased movement,
Clinical oncologists have long been haunted by the silent shift that occurs when a patient who was once responding to treatment suddenly sees their tumor markers climb without any obvious external cause. This phenomenon, particularly in advanced prostate cancer, represents one of the most
The standard medical narrative has long insisted that lower cholesterol levels are synonymous with better health outcomes, yet recent large-scale data suggests a far more nuanced reality exists for the general population. A comprehensive 2025 study involving nearly half a million participants from
Ivan Kairatov is a prominent Biopharma expert with an extensive background in biotechnology innovation and clinical research development. His work focuses on how emerging therapies transition from laboratory breakthroughs to bedside applications, particularly in the realm of chronic metabolic
The historical assumption that a plant-based diet serves as an infallible shield against all forms of malignancy is being challenged by a massive longitudinal study involving 1.8 million participants. Published in the British Journal of Cancer , this research tracked five distinct dietary groups
